Annals of Oncology 14:178-179, 2003
© 2003 European Society for Medical Oncology
Editorial |
Prediction of response to therapy by biomolecular markers: from the research laboratory to the clinic
Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano, Italy. *(E-mail: menard@istitutotumori.mi.it)
| The first 10% of the full text of this article appears below. |
Platinum-based therapy has demonstrated efficacy in the treatment of several types of epithelial tumors [13], although responses to almost all chemotherapeutic drugs have been heterogeneous. It is this heterogeneity in clinical response that motivates researchers in efforts to identify tumor biological markers useful in identifying patients who will actually benefit from a specific treatment. The differential expression of molecules likely to be involved in the sensitivity of